Gemcitabine, Cisplatin, and Celecoxib Treatment of Metastatic Pancreatic Cancer
NCT ID: NCT00176813
Last Updated: 2008-05-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
5 participants
INTERVENTIONAL
2003-03-31
2006-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This is a phase II clinical trial studying the reactions of the patient's body and their tumor to the combination of gemcitabine, cisplatin, and celecoxib. The purpose of this study is to see if the tumor responds to this treatment and to determine how long the response lasts. This study will also look at what kind of side effects this experimental treatment causes and see how often these side effects occur. Blood levels of celecoxib will be measured to find out how this treatment affects factors (proteins) involved in new blood vessel formation and tumor growth (angiogenesis).
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Gemcitabine
Cisplatin
Celecoxib
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients must have clinical/radiologic evidence of metastatic disease (stage IV).
3. Patients must not have received prior chemotherapy for metastatic disease. Prior adjuvant chemotherapy is allowed, provided that the last day of therapy was at least 6 months prior to starting treatment.
4. Patients must have performance status of 0-2 on the SWOG scale.
5. Patients must have an estimated life expectancy of at least 12 weeks.
6. Patients must have adequate bone marrow function: absolute neutrophil count \>1,500/cmm, platelet count \>100,000/cmm.
7. Patients must be informed of the investigational nature of this study and must give written informed consent prior to the receiving of treatment per this protocol.
8. Patients must practice effective birth control while receiving treatment.
Exclusion Criteria
2. Patients with locally advanced pancreatic cancer.
3. Patients with a proven history (radiographic and/or endoscopic) of peptic ulcer or esophageal erosions within one year of enrollment onto the study.
4. Patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other non-steroidal anti-inflammatory drugs.
5. History of active central nervous system (CNS) metastases.
6. Inadequate liver function (bilirubin \>3.0 mg/dL); transaminases (AST/ALT) \>3 times upper limit of institutional normal.
7. Inadequate renal function (creatinine \>1.5 mg/dL).
8. Serious concomitant systemic disorders incompatible with the study (at the discretion of the investigator).
9. History of other malignancy, except for cancers that have been treated with a curative intent and patient is without evidence of active disease.
10. Unresolved bacterial infection requiring treatment with antibiotics.
11. Pregnant or lactating women may not participate in the study.
12. Patients who have allergy to any of the study drugs or sulfa drugs.
13. Patients infected with HIV-1 virus because of the undetermined effect of this chemotherapy regimen in patients with HIV-1 and the potential for serious interaction with anti-HIV medications.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eli Lilly and Company
INDUSTRY
Barbara Ann Karmanos Cancer Institute
OTHER
University of Michigan Rogel Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
University of Michigan Comprehensive Cancer Center
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mark Zalupski, M.D.
Role: PRINCIPAL_INVESTIGATOR
University of Michigan Rogel Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Michigan
Ann Arbor, Michigan, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
C2442
Identifier Type: -
Identifier Source: secondary_id
UMCC 2001-071
Identifier Type: -
Identifier Source: org_study_id